Aprea Therapeutics (NASDAQ:APRE) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a report issued on Thursday morning, Benzinga reports. They currently have a $20.00 price objective on the stock.

Separately, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Performance

Shares of APRE opened at $3.90 on Thursday. The stock’s 50 day moving average is $3.25 and its two-hundred day moving average is $4.11. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85. The firm has a market capitalization of $21.18 million, a PE ratio of -1.17 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. On average, sell-side analysts predict that Aprea Therapeutics will post -2.74 EPS for the current year.

Insider Activity

In other news, Director Marc Duey acquired 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was purchased at an average cost of $4.39 per share, with a total value of $131,700.00. Following the purchase, the director now directly owns 240,113 shares of the company’s stock, valued at approximately $1,054,096.07. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In other Aprea Therapeutics news, Director Marc Duey acquired 30,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were purchased at an average cost of $4.39 per share, with a total value of $131,700.00. Following the purchase, the director now owns 240,113 shares in the company, valued at approximately $1,054,096.07. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bernd R. Seizinger bought 10,000 shares of the company’s stock in a transaction on Friday, October 11th. The shares were acquired at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the acquisition, the director now directly owns 44,730 shares in the company, valued at $119,876.40. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 42,290 shares of company stock worth $165,096. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.